

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
16 June 2005 (16.06.2005)

PCT

(10) International Publication Number
WO 2005/054862 A1

(51) International Patent Classification⁷: **G01N 33/574, C07K 16/00, A61K 38/16**

(74) Agent: **HARRISON GODDARD FOOTE; 31 St. Saviourgate, York YO1 8NQ (GB).**

(21) International Application Number:

PCT/GB2004/003899

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:

13 September 2004 (13.09.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0328106.0	4 December 2003 (04.12.2003)	GB
0404242.0	26 February 2004 (26.02.2004)	GB
60/554,852	19 March 2004 (19.03.2004)	US

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/CH]; Postfach, CH-8024 Zurich (CH).**

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/054862 A1

(54) Title: **SCREENING ASSAY AND TREATMENT**

(57) Abstract: The invention relates to screening assays for the identification of agents which modulate the activity of polypeptides which affect the apoptotic activity of the tumour suppressor protein p53 and including gene therapy vectors comprising p53 and antibodies that bind phosphorylated epitopes.